Stocksigma LogoStocksigma Logo

Astonea Labs Posts Strong H1 FY27 Growth and Outlines Aggressive Multi-Year Targets

Astonea Labs delivered robust consolidated H1 FY27 performance, with revenue surging 44.6% YoY to ₹95.86 Cr, EBITDA jumping 140.7% YoY to ₹13.20 Cr (margin

Astonea Labs Posts Strong H1 FY27 Growth and Outlines Aggressive Multi-Year Targets

Astonea Labs Ltd · Financial Result · 14 Nov 2026, 11:25 pm

Astonea Labs Posts Strong H1 FY27 Growth and Outlines Aggressive Multi-Year Targets Astonea Labs delivered robust consolidated H1 FY27 performance, with revenue surging 44.6% YoY to ₹95.86 Cr, EBITDA jumping 140.7% YoY to ₹13.20 Cr (margin expanded 550 bps to 13.8%), and PAT rising 153.3% YoY to ₹4.82 Cr. The board approved acquiring a 51% stake in Longevity Science Pvt Ltd. Management guided for FY27 revenue of ₹215+ Cr with a 13–15% EBITDA margin, targeting ₹300+ Cr in FY28 and ₹405+ Cr in FY29 (~40% CAGR from FY26), driven by domestic OTC brands and export expansion.

Original exchange filing (PDF)

More announcements from Astonea Labs Ltd

All Astonea Labs Ltd announcements